Trade GeoVax Labs, Inc. - GOVX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0342 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023429% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001207% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.748 |
| Open | 0.772 |
| 1-Year Change | -48.14% |
| Day's Range | 0.772 - 0.8067 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 21, 2025 | 0.7480 | -0.0678 | -8.31% | 0.8158 | 0.8158 | 0.7318 |
| Apr 17, 2025 | 0.8094 | -0.0884 | -9.85% | 0.8978 | 0.8978 | 0.7946 |
| Apr 16, 2025 | 0.8858 | 0.0540 | 6.49% | 0.8318 | 0.9428 | 0.8218 |
| Apr 15, 2025 | 0.8418 | 0.0700 | 9.07% | 0.7718 | 0.9005 | 0.7217 |
| Apr 14, 2025 | 1.0518 | 0.0400 | 3.95% | 1.0118 | 1.0518 | 1.0018 |
| Apr 11, 2025 | 0.9818 | 0.0020 | 0.20% | 0.9798 | 1.0818 | 0.9798 |
| Apr 10, 2025 | 0.9419 | -0.0599 | -5.98% | 1.0018 | 1.0118 | 0.9228 |
| Apr 9, 2025 | 1.0318 | 0.0648 | 6.70% | 0.9670 | 1.0518 | 0.8918 |
| Apr 8, 2025 | 0.9618 | 0.0001 | 0.01% | 0.9617 | 1.0418 | 0.9518 |
| Apr 7, 2025 | 0.9439 | 0.0121 | 1.30% | 0.9318 | 1.0218 | 0.8522 |
| Apr 4, 2025 | 1.0118 | -0.0300 | -2.88% | 1.0418 | 1.0518 | 0.9918 |
| Apr 3, 2025 | 1.0618 | -0.0400 | -3.63% | 1.1018 | 1.1018 | 1.0518 |
| Apr 2, 2025 | 1.1718 | 0.1000 | 9.33% | 1.0718 | 1.1918 | 1.0718 |
| Apr 1, 2025 | 1.0518 | -0.0300 | -2.77% | 1.0818 | 1.1218 | 1.0218 |
| Mar 31, 2025 | 1.0518 | -0.0300 | -2.77% | 1.0818 | 1.0918 | 1.0518 |
| Mar 28, 2025 | 1.1018 | -0.1000 | -8.32% | 1.2018 | 1.2418 | 1.0918 |
| Mar 27, 2025 | 1.2618 | -0.0900 | -6.66% | 1.3518 | 1.3518 | 1.2618 |
| Mar 26, 2025 | 1.3618 | 0.0000 | 0.00% | 1.3618 | 1.3818 | 1.3418 |
| Mar 25, 2025 | 1.3618 | -0.0200 | -1.45% | 1.3818 | 1.3818 | 1.3418 |
| Mar 24, 2025 | 1.3818 | 0.1200 | 9.51% | 1.2618 | 1.3918 | 1.1918 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
GeoVax Labs, Inc. Company profile
About Geovax Labs Inc
GeoVax Labs, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human vaccines and immunotherapies against infectious diseases and cancer using its platforms. Its product pipeline includes ongoing human clinical trials for COVID-19 and head and neck cancer. The Company is developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. The Company’s product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02, GEO-EM01, GEO-LM01 and GEO-MM02. Its research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s wholly owned subsidiaries include GeoVax, Inc. and Immutak Oncology, Inc.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Geovax Labs Inc revenues decreased 79% to $386K. Net loss increased from $3M to $18.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from $2.4M to $15.6M (expense), General and administrative increase of 63% to $3.6M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 40M auth., 15,699,909 issd. Insiders control approx. 39.31%. IPO: NA. Private Placement: 1997, 4.4M shares @ $1. 9/06, Co. acq. by GeoVax, Inc. & name changed from Dauphin Technology, Inc. 04/10, 1-for-50 reverse split.
| Industry: | Biotechnology & Medical Research (NEC) |
1900 Lake Park Drive
Suite 380
SMYRNA
GEORGIA 30080
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com